Evommune (EVMN) Liabilities and Shareholders Equity (2024 - 2026)

Evommune (EVMN) has 3 years of Liabilities and Shareholders Equity data on file, last reported at $322.5 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity changed N/A year-over-year to $322.5 million in Q1 2026; TTM through Mar 2026 was $631.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $224.9 million, up 195.77% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $322.5 million, up from $224.9 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for EVMN reached as high as $322.5 million in Q1 2026 and fell as low as $76.1 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $177.0 million across 3 years, with a median of $154.7 million in 2025.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 195.77% in 2025 and fell as far as 195.77% in 2025.
• Year by year, Liabilities and Shareholders Equity stood at $76.1 million in 2024, then soared by 195.77% to $224.9 million in 2025, then surged by 43.35% to $322.5 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $322.5 million in Q1 2026, $224.9 million in Q4 2025, and $84.5 million in Q3 2025.